AACR Annual Meeting 2026

Novalix is pleased to announce its participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting, one of the world’s leading scientific gatherings dedicated to advancing cancer research and patient care. The company will present a scientific poster highlighting ongoing research efforts in oncology.

The AACR Annual Meeting brings together researchers, clinicians, industry leaders, and patient advocates from around the globe to share the latest discoveries spanning cancer biology, translational science, clinical development, prevention, and survivorship. Participation in this forum underscores Novalix’s commitment to contributing to the global fight against cancer through innovative research and collaboration.

Poster presentation: ASTU‑045, a novel METTL3 inhibitor with anti‑tumor activity in the MC38 syngeneic mouse model

We are proud to announce that Dr Laurence Mévellec, Senior Research Fellow Drug Discovery, will share our latest research with a poster presentation, reflecting our continued focus on advancing novel approaches in oncology.

Key highlights:
▪️ Discovery of ASTU‑045, a novel and selective METTL3 inhibitor
▪️ Clear cellular target engagement and enhancement of immune anti‑tumor activity
▪️ 𝐼𝑛 𝑣𝑖𝑣𝑜 efficacy in the MC38 syngeneic mouse model and enhanced anti‑tumor response when combined with anti‑PD‑1 therapy

Developed in collaboration with Aqemia, this work further highlights the therapeutic potential of METTL3 inhibition to modulate the tumor microenvironment and boost anti‑tumor immunity.

Poster Session PO.ET09.01 – Epigenetic Modulators 1, poster #4485

Through its presence at AACR, Novalix reinforces its dedication to scientific excellence and its mission to develop impactful solutions for people affected by cancer.

Contact us to know more about our services, and to explore how Novalix can support your drug discovery challenges from the earliest stages to candidate selection!